Prevention Of Radiation Induced Nausea And Vomiting — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevention of radiation induced nausea and vomiting. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2029. Daily refresh.

1
Approved drugs
4
Active US patents
51/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevention Of Radiation Induced Nausea And Vomiting

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

GSK (originally Glaxo) 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevention of radiation induced nausea and vomiting. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
29
2
30

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Zofran
ondansetron
 GSK (originally Glaxo) 4 51 — 2029-11-23

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8580830 Zofran formulation 53 2029-11-23
8580830 Zofran formulation 53 2029-11-23
9095577 Zofran formulation 48 2030-07-13
9095577 Zofran formulation 48 2030-07-13

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9095577 Zofran formulation 48 2030-07-13
9095577 Zofran formulation 48 2030-07-13
8580830 Zofran formulation 53 2029-11-23
8580830 Zofran formulation 53 2029-11-23

Related